Autolus Therapeutics (AUTL) Long-Term Deferred Tax (2019 - 2026)

Autolus Therapeutics (AUTL) has 7 years of Long-Term Deferred Tax data on file, last reported at $3.6 million in Q4 2025.

• Quarterly Long-Term Deferred Tax rose 9.91% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.6 million (up 9.91% YoY) and the FY2025 annual result came in at $3.6 million, up 9.91% from the prior year.
• Long-Term Deferred Tax climbed to $3.6 million in Q4 2025, from $2.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $3.6 million in Q4 2025 to a low of $1.4 million in Q3 2021.
• A 5-year average of $2.5 million and a median of $2.4 million in 2022 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2021 — Long-Term Deferred Tax surged 396.1% — and 2025, when it slipped 29.51%.
• Tracing AUTL's Long-Term Deferred Tax over 5 years: stood at $1.8 million in 2021, then gained by 13.69% to $2.1 million in 2022, then jumped by 47.54% to $3.1 million in 2023, then increased by 5.75% to $3.2 million in 2024, then grew by 9.91% to $3.6 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $3.6 million (Q4 2025), $2.4 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.